NICE rules against first-line use of Ipsen’s Cabometyx

5th June 2018 Uncategorised 0

The National Institute for Health and Care Excellence has issued a preliminary decision rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on the NHS.

More: NICE rules against first-line use of Ipsen’s Cabometyx
Source: News